STUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.
E. David Crawford, MD
A 65-year-old woman presented to a local emergency department complaining of right flank pain that had worsened over the past 10 days. A CT scan of the abdomen and pelvis showed intravesical tumors of the urinary bladder.
A 59-year-old man with metastatic gastric cancer presented to the oncology clinic with a 1-week history of positional headache, nausea, and vomiting. He stated that the headache was located in the frontal region, was 8 on a scale of 10 in intensity.
This article reviews recent evidence suggesting an increased risk of pneumonia, cardiovascular disease, and acute kidney injury in men treated with ADT and consider whether the incidence of such events differs with the treatment modality.
(18)F-NaF PET/CT and (11)C-Choline PET/CT for the Initial Detection of Metastatic Disease in Prostate Cancer: Overview and Potential Utilization
We briefly review these two imaging technologies and provide potential utilization strategies based on available data.
A 63-year-old man with no family history of prostate cancer has prostate biopsy that revealed 9 out of 12 cores involved with prostatic adenocarcinoma, mostly Gleason score 5+4=9.
In the past 5 years we have taken at least 7 steps forward for men with prostate cancer—which hopefully will turn into “one giant leap” in our attempt to convert advanced prostate cancer into a chronic disease.
In this article, we review recent advances in the discovery of prostate cancer biomarkers, their integration into clinical practice, and implications for improving clinical management of the disease.
A 46-year-old man sought consultation for an abnormal prostate-specific antigen (PSA) level of 9 ng/mL and one prior negative biopsy. Five months ago, while traveling, he had presented to an urgent care facility with a 24-hour history of fever, chills, nausea, and vomiting.
We have entered a period of accelerated drug development and optimism in the care of advanced prostate cancer. The treatment paradigm for these patients is rapidly evolving, with future study needed to define the optimal sequencing and potential combinations of these new agents.